Aurinia Pharmaceuticals Q4 EPS at $0.26 Doubles From Year Ago, Tops Estimates
Aurinia Pharmaceuticals posted adjusted EPS of $0.26 for the quarter ended December 31, 2025, surpassing the $0.21 consensus by $0.05 and rising from $0.09 a year earlier. The company also released full-year 2025 results and outlined recent business progress including pipeline advancement and operational milestones.
1. Q4 Earnings Performance
Aurinia Pharmaceuticals reported adjusted earnings per share of $0.26 for the quarter ended December 31, 2025, compared with the Zacks consensus estimate of $0.21. This marks a year-over-year increase from $0.09 in Q4 2024 and represents a $0.05 upside to expectations.
2. Full-Year Results & Business Update
Alongside its quarterly report, Aurinia released full-year 2025 financial results and provided an update on recent business progress. Highlights included pipeline advancement milestones and operational achievements designed to support upcoming clinical and commercial objectives.